68Ga-PSMA PET/CT 在前列腺癌根治性治疗后复发患者中的应用:314 例前瞻性结果
该前瞻性研究纳入 314 例根治性手术和/或放疗后生化复发的前列腺癌患者,行 68Ga-PSMA PET/CT 检测复发。197 例(62.7%)阳性,PET 阳性者 PSApet 高于阴性者(P < 0.0001);88 例胆碱 PET/CT 阴性者中 59 例(67%)68Ga-PSMA PET/CT 阳性。作者认为 68Ga-PSMA PET/CT 在生化复发再分期中有价值,性能优于胆碱 PET/CT。
要点
- 314 例生化复发前列腺癌患者中 68Ga-PSMA PET/CT 阳性 197 例(62.7%)。
- 阳性病灶局限于盆腔者 117 例(59.4%),至少一处远处病灶者 80 例(40.6%)。
- 88 例胆碱 PET/CT 阴性者中 59 例(67%)68Ga-PSMA PET/CT 阳性。
核心结论
- 作者确认 68Ga-PSMA PET/CT 在生化复发前列腺癌患者再分期中的价值,并强调其性能与安全性优于胆碱 PET/CT。
- PSApet 越高,复发检出率越高。
研究设计与样本
- 前瞻性研究,纳入根治性手术和/或放疗(联合或不联合雄激素剥夺治疗)后生化复发的前列腺癌患者。
- 2015 年 11 月至 2017 年 10 月共评估 314 例患者,中位年龄 70 岁(范围 44–92 岁),中位 PSApet 0.83 ng/ml(范围 0.003–80.0 ng/ml)。
- 静脉注射 150 ± 50 MBq 68Ga-PSMA 后 60 分钟行头顶至大腿中段 PET/CT,由两名核医学医师判读。
- 结果与扫描时 PSA 水平(PSApet)、PSA 倍增时间、Gleason 评分、肿瘤分期、术后肿瘤残留、原发治疗至生化复发时间及患者年龄进行相关性分析。
- 有可用资料时,将 68Ga-PSMA PET/CT 与之前 1 个月内常规进行的阴性 18F-胆碱 PET/CT 比较。
主要发现
- 68Ga-PSMA PET/CT 阳性(检出至少一处可疑前列腺癌病灶)197 例(62.7%)。
- 病灶局限于盆腔(前列腺/前列腺床和/或盆腔淋巴结)117 例(59.4%);至少一处远处病灶(淋巴结、骨、其他器官,单独或与局部病灶合并)80 例(40.6%)。
- PET 阳性患者 PSApet 高于 PET 阴性患者(P < 0.0001)。
- 88 例胆碱 PET/CT 阴性患者中,59 例(67%)68Ga-PSMA PET/CT 阳性。
关键数值与推荐
- 68Ga-PSMA PET/CT 阳性定义为检出至少一处可疑前列腺癌病灶。
- PET 阳性患者 PSApet 高于 PET 阴性患者(P < 0.0001)。
- 88 例胆碱 PET/CT 阴性患者中 59 例(67%)68Ga-PSMA PET/CT 阳性。
临床怎么用
- 作者确认 68Ga-PSMA PET/CT 在生化复发前列腺癌患者再分期中的价值,并强调其性能与安全性优于胆碱 PET/CT。
- PSApet 越高,复发检出率越高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We studied the usefulness of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT for detecting relapse in a prospective series of patients with biochemical recurrence (BCR) of prostate cancer (PCa) after radical treatment. METHODS: Patients with BCR of PCa after radical surgery and/or radiotherapy with or without androgen-deprivation therapy were included in the study. 68Ga-PSMA PET/CT scans performed from the top of the head to the mid-thigh 60 min after intravenous injection of 150 ± 50 MBq of 68Ga-PSMA were interpreted by two nuclear medicine physicians. The results were correlated with prostate-specific antigen (PSA) levels at the time of the scan (PSApet), PSA doubling time, Gleason score, tumour stage, postsurgery tumour residue, time from primary therapy to BCR, and patient age. When available, 68Ga-PSMA PET/CT scans were compared with negative 18F-choline PET/CT scans routinely performed up to 1 month previously. RESULTS: From November 2015 to October 2017, 314 PCa patients with BCR were evaluated. Their median age was 70 years (range 44-92 years) and their median PSApet was 0.83 ng/ml (range 0.003-80.0 ng/ml). 68Ga-PSMA PET/CT was positive (one or more suspected PCa lesions detected) in 197 patients (62.7%). Lesions limited to the pelvis, i.e. the prostate/prostate bed and/or pelvic lymph nodes (LNs), were detected in 117 patients (59.4%). At least one distant lesion (LNs, bone, other organs, separately or combined with local lesions) was detected in 80 patients (40.6%). PSApet was higher in PET-positive than in PET-negative patients (P < 0.0001). Of 88 patients negative on choline PET/CT scans, 59 (67%) were positive on 68Ga-PSMA PET/CT. CONCLUSION: We confirmed the value of 68Ga-PSMA PET/CT in restaging PCa patients with BCR, highlighting its superior performance and safety compared with choline PET/CT. Higher PSApet was associated with a higher relapse detection rate.
引用
- Caroli P, Sandler I, Matteucci F, et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018. PMID: 29922948. doi:10.1007/s00259-018-4067-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。